One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings By: Benzinga via Benzinga April 17, 2018 at 14:16 PM EDT Merck & Co., Inc. (NYSE: MRK)’s Keytruda returned better-than-expected results in the Keynote-189 lung study — a feat ... Read More >> Related Stocks: Bristol-Myers Squibb Merck & Co